|Articles|October 12, 2016

FDA Signs CRADA with CluePoints

The FDA has signed a Cooperative Research and Development Agreement (CRADA) with CluePoints for its Central Statistical Monitoring solution.

The FDA has signed a Cooperative Research and Development Agreement (CRADA) with CluePoints for its Central Statistical Monitoring solution to explore a data driven approach to selecting sites which exhibit data anomalies indicative of fraud, misconduct or sloppiness.

Read the full release here

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Subscribe Now!

Related Content

© photon_photo - © photon_photo - stock.adobe.com

FDA Signs CRADA with CluePoints

Newsletter

Related Content

Drug Repurposing Through AI-Driven In-Silico Clinical Trials

ACT Brief: CNS Trial Expansion, Vaccine Policy Debate, and New Leadership at FDA

Obesity Trials: Scaling Operations for High-Demand Therapeutics

Former FDA Commissioners Warn New Vaccine Policies Could Undermine Longstanding Regulatory Framework

ACT Brief: Targeted Trial Growth, Site Startup Strains, and Leadership Shake-Up at FDA

Trending on Applied Clinical Trials Online

Former FDA Commissioners Warn New Vaccine Policies Could Undermine Longstanding Regulatory Framework

How the FDA’s CNPV Program Is Reshaping Trial Operations and Accelerated Review Strategies

Voyxact Lands FDA Accelerated Approval Following Positive Results in Phase III VISIONARY Trial

ACT Brief: Targeted Trial Growth, Site Startup Strains, and Leadership Shake-Up at FDA

New ICON Survey Shows Sites Face Growing Delays and Communication Gaps During Study Startup